ArticleRheumatology and therapy2024

Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.

Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.